trending Market Intelligence /marketintelligence/en/news-insights/trending/J1CNf0R8dFeLx98YFNhBwA2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

Achaogen prices common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Achaogen prices common stock offering

Achaogen Inc. priced an underwritten public offering of 6.5 million common shares at a per-share price of $13.50 for $87.8 million in gross proceeds.

The company has granted the underwriters an option to buy up to an additional 975,000 shares.

Achaogen intends to use the net proceeds to fund the ongoing development and preparation for potential commercialization of plazomicin. The remaining net proceeds will be used for working capital and general corporate purposes, including research and development of additional product candidates.

The offering is expected to close Dec. 19, subject to satisfaction of customary closing conditions.

Leerink Partners LLC, Stifel and Guggenheim Securities LLC are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey Inc. is acting as lead manager for the offering.